Astrazeneca Pharma India Achieves 52-Week High Amid Strong Financial Performance

Astrazeneca Pharma India has made headlines today as its stock price reached a new 52-week high of Rs. 9049.95, marking a significant milestone for the company. This achievement comes amid a strong performance, with the stock outperforming its sector by 3.45% and gaining 12.25% over the last three days. The stock has consistently traded above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a robust upward trend.
In terms of financial health, Astrazeneca Pharma India boasts a high return on equity (ROE) of 19.06% and a low debt-to-equity ratio, reflecting strong management efficiency. The company reported impressive quarterly results, with net sales reaching Rs. 440.29 crore and an operating profit margin of 17.49%. Over the past year, the stock has delivered a remarkable return of 75.26%, significantly outpacing the Sensex's performance of 6.02%.

As a large-cap player in the pharmaceuticals and drugs industry, Astrazeneca Pharma India continues to demonstrate resilience and growth, solidifying its position among the top-rated companies in the market.